JP7748974B2 - トゥレット症候群の治療のためのホスホジエステラーゼ１０阻害剤の使用 - Google Patents

トゥレット症候群の治療のためのホスホジエステラーゼ１０阻害剤の使用

Info

Publication number
JP7748974B2
JP7748974B2 JP2022574676A JP2022574676A JP7748974B2 JP 7748974 B2 JP7748974 B2 JP 7748974B2 JP 2022574676 A JP2022574676 A JP 2022574676A JP 2022574676 A JP2022574676 A JP 2022574676A JP 7748974 B2 JP7748974 B2 JP 7748974B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
therapeutic agent
administered
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022574676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528896A (ja
JP2023528896A5 (https=
Inventor
ゲオルク ガリバルディ
Original Assignee
ノエマ ファーマ アクツィエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノエマ ファーマ アクツィエンゲゼルシャフト filed Critical ノエマ ファーマ アクツィエンゲゼルシャフト
Publication of JP2023528896A publication Critical patent/JP2023528896A/ja
Publication of JP2023528896A5 publication Critical patent/JP2023528896A5/ja
Priority to JP2025156736A priority Critical patent/JP2025183391A/ja
Application granted granted Critical
Publication of JP7748974B2 publication Critical patent/JP7748974B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2022574676A 2020-06-05 2021-06-04 トゥレット症候群の治療のためのホスホジエステラーゼ１０阻害剤の使用 Active JP7748974B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025156736A JP2025183391A (ja) 2020-06-05 2025-09-22 トゥレット症候群の治療のためのホスホジエステラーゼ１０阻害剤の使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063035310P 2020-06-05 2020-06-05
US63/035,310 2020-06-05
US202163160302P 2021-03-12 2021-03-12
US63/160,302 2021-03-12
PCT/EP2021/065074 WO2021245280A1 (en) 2020-06-05 2021-06-04 Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025156736A Division JP2025183391A (ja) 2020-06-05 2025-09-22 トゥレット症候群の治療のためのホスホジエステラーゼ１０阻害剤の使用

Publications (3)

Publication Number Publication Date
JP2023528896A JP2023528896A (ja) 2023-07-06
JP2023528896A5 JP2023528896A5 (https=) 2024-06-12
JP7748974B2 true JP7748974B2 (ja) 2025-10-03

Family

ID=76325557

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022574676A Active JP7748974B2 (ja) 2020-06-05 2021-06-04 トゥレット症候群の治療のためのホスホジエステラーゼ１０阻害剤の使用
JP2025156736A Pending JP2025183391A (ja) 2020-06-05 2025-09-22 トゥレット症候群の治療のためのホスホジエステラーゼ１０阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025156736A Pending JP2025183391A (ja) 2020-06-05 2025-09-22 トゥレット症候群の治療のためのホスホジエステラーゼ１０阻害剤の使用

Country Status (13)

Country Link
US (2) US11883385B2 (https=)
EP (1) EP4161526A1 (https=)
JP (2) JP7748974B2 (https=)
KR (2) KR20250171459A (https=)
CN (2) CN116137811B (https=)
AU (1) AU2021285225A1 (https=)
BR (1) BR112022024751A2 (https=)
CA (1) CA3180793A1 (https=)
CL (2) CL2022003400A1 (https=)
IL (1) IL298713A (https=)
MX (1) MX2022015400A (https=)
PH (1) PH12023550007A1 (https=)
WO (1) WO2021245280A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12544364B2 (en) * 2020-06-05 2026-02-10 Noema Pharma Ag Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
WO2022162193A1 (en) * 2021-01-28 2022-08-04 Noema Pharma Ag Methods for the treatment of childhood-onset fluency disorder
WO2026068583A1 (en) * 2024-09-25 2026-04-02 Noema Pharma Ag Use of phosphodiesterase 10 inhibitor gemlapodect for weight loss

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544859A (ja) 2010-12-07 2013-12-19 エフ．ホフマン−ラ ロシュ アーゲー トリアゾロピリジン化合物
JP2014524471A (ja) 2011-08-25 2014-09-22 メルク・シャープ・アンド・ドーム・コーポレーション ピリミジンｐｄｅ１０阻害剤
JP2015042659A (ja) 2013-02-27 2015-03-05 持田製薬株式会社 新規ピラゾール誘導体
JP2016520047A (ja) 2013-04-30 2016-07-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾールアミドのＰｄ触媒カップリング

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
EP1723134A2 (en) * 2004-02-18 2006-11-22 Pfizer Products Incorporated Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
PL3919060T3 (pl) * 2012-07-12 2025-10-20 Emalex Biosciences, Inc. Ekopipam do leczenia zespołu tourette'a

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544859A (ja) 2010-12-07 2013-12-19 エフ．ホフマン−ラ ロシュ アーゲー トリアゾロピリジン化合物
JP2014524471A (ja) 2011-08-25 2014-09-22 メルク・シャープ・アンド・ドーム・コーポレーション ピリミジンｐｄｅ１０阻害剤
JP2015042659A (ja) 2013-02-27 2015-03-05 持田製薬株式会社 新規ピラゾール誘導体
JP2016520047A (ja) 2013-04-30 2016-07-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾールアミドのＰｄ触媒カップリング

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MSDマニュアル プロフェッショナル版 小児及び青年におけるトゥレット症候群，2023年03月，検索日［令和７年３月１８日］,インターネット＜https://www.msdmanuals.com/ja-jp/professional/19-%E5%B0%8F%E5%85%90%E7%A7%91/%E5%B0%8F%E5%85%90%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E7%A5%9E%E7%B5%8C%E7%96%BE%E6%82%A3/%E5%B0%8F%E5%85%90%E3%81%8A%E3%82%88%E3%81%B3%E9%9D%92%E5%B9%B4%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E3%83%81%E3%83%83%E3%82%AF%E7%97%87%E3%81%8A%E3%82%88%E3%81%B3%E3%83%88%E3%82%A5%E3%83%AC%E3%83%83%E3%83%88%E7%97%87%E5%80%99%E7%BE%A4＞
NCNP病院 国立精神・神経医療研究センター チック症・トゥレット症，2025年02月，検索日［令和７年３月１８日］,インターネット＜http://web.archive.org/web/20250227101308/https://www.ncnp.go.jp/hospital/patient/disease16.html＞
Progress in Neuro-Psychopharmacology & Biological Psychiatry，2002年，Vol.26，pp.1245-1252

Also Published As

Publication number Publication date
CN116137811A (zh) 2023-05-19
KR102892626B1 (ko) 2025-11-28
CA3180793A1 (en) 2021-12-09
CN116137811B (zh) 2026-01-09
BR112022024751A2 (pt) 2023-03-07
CN121891333A (zh) 2026-04-21
IL298713A (en) 2023-02-01
CL2022003400A1 (es) 2023-07-28
US20260076950A1 (en) 2026-03-19
JP2025183391A (ja) 2025-12-16
US11883385B2 (en) 2024-01-30
AU2021285225A1 (en) 2023-01-19
WO2021245280A1 (en) 2021-12-09
EP4161526A1 (en) 2023-04-12
MX2022015400A (es) 2023-03-16
WO2021245280A9 (en) 2022-01-27
CL2025002636A1 (es) 2025-11-28
US20230149372A1 (en) 2023-05-18
PH12023550007A1 (en) 2024-03-11
JP2023528896A (ja) 2023-07-06
KR20230040978A (ko) 2023-03-23
KR20250171459A (ko) 2025-12-08

Similar Documents

Publication Publication Date Title
JP2025183391A (ja) トゥレット症候群の治療のためのホスホジエステラーゼ１０阻害剤の使用
TW200911265A (en) Pharmaceutical compositions and methods of treating dry eye disorders
JP2022130689A (ja) Ｓｇｃ刺激剤の固体形態
TW201632511A (zh) 治療精神分裂症之組成物及方法
JP7634987B2 (ja) Ｈ３－リガンドの新たな治療用途
EA021962B1 (ru) Способ лечения шизофрении
JP2019502686A (ja) 消化管括約筋機能障害の治療へのｓＧＣ刺激薬の使用
JP2025106456A (ja) 胆管癌を治療するための方法
EP4349341A1 (en) Pharmaceutical preparation for preventing or treating pulmonary fibrosis
CA3148939A1 (en) Compositions and methods for the treatment of estrogen-dependent disorders
US20230381193A1 (en) Methods for the treatment of childhood-onset fluency disorder
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
US12544364B2 (en) Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
CN104902891B (zh) 治疗和预防创伤性脑损伤性神经元损害的组合物和方法
OA21483A (en) Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome.
US20170196883A1 (en) Derivatives of 7-fluoro-8-chloro-5h-dibenzo [b,e,] [1,4] diazepine and use thereof
WO2026068583A1 (en) Use of phosphodiesterase 10 inhibitor gemlapodect for weight loss
CN117157077A (zh) 儿童期发病的流畅性障碍的治疗方法
JP4598674B2 (ja) 統合失調症治療剤
WO2024073328A2 (en) Methods of treating cancer and compositions for the same
JP2023545367A (ja) バソプレシン受容体拮抗薬療法の副作用を管理する方法
CN121666238A (zh) 阿匹莫德组合物和使用方法
CN103254127A (zh) 甘氨酸重摄取抑制剂及其应用
WO2013075624A1 (zh) 甘氨酸重摄取抑制剂及其应用

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240604

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250624

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250922

R150 Certificate of patent or registration of utility model

Ref document number: 7748974

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150